Structural basis of HIV-1 tethering to membranes by the BST-2/tetherin ectodomain.

The restriction factor BST-2/tetherin contains two membrane anchors employed to retain some enveloped viruses, including HIV-1 tethered to the plasma membrane in the absence of virus-encoded antagonists. The 2.77 A crystal structure of the BST-2/tetherin extracellular core presented here reveals a parallel 90 A long disulfide-linked coiled-coil domain, while the complete extracellular domain forms an extended 170 A long rod-like structure based on small-angle X-ray scattering data. Mutagenesis analyses indicate that both the coiled coil and the N-terminal region are required for retention of HIV-1, suggesting that the elongated structure can function as a molecular ruler to bridge long distances. The structure reveals substantial irregularities and instabilities throughout the coiled coil, which contribute to its low stability in the absence of disulfide bonds. We propose that the irregular coiled coil provides conformational flexibility, ensuring that BST-2/tetherin anchoring both in the plasma membrane and in the newly formed virus membrane is maintained during virus budding.

[1]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[2]  George M Sheldrick,et al.  Substructure solution with SHELXD. , 2002, Acta crystallographica. Section D, Biological crystallography.

[3]  Randy J Read,et al.  Electronic Reprint Biological Crystallography Phenix: Building New Software for Automated Crystallographic Structure Determination Biological Crystallography Phenix: Building New Software for Automated Crystallographic Structure Determination , 2022 .

[4]  P. Bates,et al.  Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein , 2009, Proceedings of the National Academy of Sciences.

[5]  I. Schlichting,et al.  Crystal structures of human cardiac β-myosin II S2-Δ provide insight into the functional role of the S2 subfragment , 2006, Proceedings of the National Academy of Sciences.

[6]  A. Moses,et al.  Vpu Directs the Degradation of the Human Immunodeficiency Virus Restriction Factor BST-2/Tetherin via a βTrCP-Dependent Mechanism , 2009, Journal of Virology.

[7]  K. Jeang,et al.  Human cellular restriction factors that target HIV-1 replication , 2009, BMC medicine.

[8]  I. Prior,et al.  The Vpu-regulated endocytosis of HIV-1 Gag is clathrin-independent. , 2007, Virology.

[9]  J. Abrahams,et al.  Methods used in the structure determination of bovine mitochondrial F1 ATPase. , 1996, Acta crystallographica. Section D, Biological crystallography.

[10]  Thomas C. Terwilliger,et al.  Automated MAD and MIR structure solution , 1999, Acta crystallographica. Section D, Biological crystallography.

[11]  Marc C. Johnson,et al.  The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. , 2008, Cell host & microbe.

[12]  T. Klimkait,et al.  The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release , 1990, Journal of virology.

[13]  George Banting,et al.  Bst‐2/HM1.24 Is a Raft‐Associated Apical Membrane Protein with an Unusual Topology , 2003, Traffic.

[14]  László Nyitray,et al.  Visualization of an unstable coiled coil from the scallop myosin rod , 2003, Nature.

[15]  R. Benarous,et al.  Vpu Antagonizes BST-2–Mediated Restriction of HIV-1 Release via β-TrCP and Endo-Lysosomal Trafficking , 2009, PLoS pathogens.

[16]  D. Pillay,et al.  Mutation of a Single Residue Renders Human Tetherin Resistant to HIV-1 Vpu-Mediated Depletion , 2009, PLoS pathogens.

[17]  W. Haseltine,et al.  Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Lustig,et al.  Improving coiled-coil stability by optimizing ionic interactions. , 2002, Journal of molecular biology.

[19]  G. Phillips.  What is the pitch of the α‐helical coiled coil? , 1992 .

[20]  Marc C. Johnson,et al.  Tetherin Inhibits HIV-1 Release by Directly Tethering Virions to Cells , 2009, Cell.

[21]  Toshio Matsumoto,et al.  Interferon‐α enhances CD317 expression and the antitumor activity of anti‐CD317 monoclonal antibody in renal cell carcinoma xenograft models , 2008, Cancer science.

[22]  A. McCormack,et al.  Quantitative Membrane Proteomics Reveals New Cellular Targets of Viral Immune Modulators , 2006, PLoS pathogens.

[23]  Michael Emerman,et al.  HIV-1 accessory proteins--ensuring viral survival in a hostile environment. , 2008, Cell host & microbe.

[24]  D I Svergun,et al.  Determination of domain structure of proteins from X-ray solution scattering. , 2001, Biophysical journal.

[25]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[26]  Dmitri I. Svergun,et al.  Determination of the regularization parameter in indirect-transform methods using perceptual criteria , 1992 .

[27]  A. Sakurai,et al.  Dimerization of Tetherin Is Not Essential for Its Antiviral Activity against Lassa and Marburg Viruses , 2009, PloS one.

[28]  T. Klimkait,et al.  Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein , 1989, Journal of virology.

[29]  D I Svergun,et al.  Restoring low resolution structure of biological macromolecules from solution scattering using simulated annealing. , 1999, Biophysical journal.

[30]  M. Tsuchiya,et al.  Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. , 1999, Biochemical and biophysical research communications.

[31]  J. Luban,et al.  HIV-1 Vpu Neutralizes the Antiviral Factor Tetherin/BST-2 by Binding It and Directing Its Beta-TrCP2-Dependent Degradation , 2009, PLoS pathogens.

[32]  Sergei V Strelkov,et al.  Analysis of alpha-helical coiled coils with the program TWISTER reveals a structural mechanism for stutter compensation. , 2002, Journal of structural biology.

[33]  George M. Sheldrick,et al.  Macromolecular phasing with SHELXE , 2002 .

[34]  S. Kennel,et al.  A novel membrane antigen selectively expressed on terminally differentiated human B cells. , 1994, Blood.

[35]  T. Gramberg,et al.  Accessories to the crime: Recent advances in HIV accessory protein biology , 2009, Current HIV/AIDS reports.

[36]  K H Kim,et al.  Deciphering the design of the tropomyosin molecule , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[37]  K. Strebel,et al.  The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu , 2009, Retrovirology.

[38]  K. Strebel,et al.  Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion , 2009, Proceedings of the National Academy of Sciences.

[39]  P. Bieniasz,et al.  Species-Specific Activity of HIV-1 Vpu and Positive Selection of Tetherin Transmembrane Domain Variants , 2009, PLoS pathogens.

[40]  V. Nizet,et al.  Coiled-Coil Irregularities and Instabilities in Group A Streptococcus M1 Are Required for Virulence , 2008, Science.

[41]  B. Chesebro,et al.  Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism , 1992, Journal of virology.

[42]  H. Kräusslich,et al.  HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. , 2009, Cell host & microbe.

[43]  G. Learn,et al.  Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. , 2009, Cell host & microbe.

[44]  Dmitri I. Svergun,et al.  PRIMUS: a Windows PC-based system for small-angle scattering data analysis , 2003 .

[45]  P. Evans,et al.  Scaling and assessment of data quality. , 2006, Acta crystallographica. Section D, Biological crystallography.

[46]  G Bricogne,et al.  Generation, representation and flow of phase information in structure determination: recent developments in and around SHARP 2.0. , 2003, Acta crystallographica. Section D, Biological crystallography.

[47]  M. Wainberg,et al.  The Transmembrane Domain of BST-2 Determines Its Sensitivity to Down-Modulation by Human Immunodeficiency Virus Type 1 Vpu , 2009, Journal of Virology.

[48]  Yuko Hirota,et al.  HM1.24 Is Internalized from Lipid Rafts by Clathrin-mediated Endocytosis through Interaction with α-Adaptin* , 2009, The Journal of Biological Chemistry.

[49]  J. Mccammon,et al.  Situs: A package for docking crystal structures into low-resolution maps from electron microscopy. , 1999, Journal of structural biology.

[50]  S. Westmoreland,et al.  Species-Specific Activity of SIV Nef and HIV-1 Vpu in Overcoming Restriction by Tetherin/BST2 , 2009, PLoS pathogens.

[51]  J. Sodroski,et al.  Functional role of human immunodeficiency virus type 1 vpu. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Marc C. Johnson,et al.  Nef proteins from simian immunodeficiency viruses are tetherin antagonists. , 2009, Cell host & microbe.

[53]  T. Noda,et al.  Inhibition of Lassa and Marburg Virus Production by Tetherin , 2008, Journal of Virology.

[54]  P. Bieniasz,et al.  Broad-Spectrum Inhibition of Retroviral and Filoviral Particle Release by Tetherin , 2008, Journal of Virology.

[55]  P. Bieniasz,et al.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu , 2008, Nature.

[56]  Wolfgang Kabsch,et al.  Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants , 1993 .

[57]  W. Sundquist,et al.  An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. , 2007, Cell host & microbe.

[58]  T. Deerinck,et al.  Direct Restriction of Virus Release and Incorporation of the Interferon-Induced Protein BST-2 into HIV-1 Particles , 2010, PLoS pathogens.

[59]  H. Kräusslich,et al.  CD317/Tetherin Is Enriched in the HIV-1 Envelope and Downregulated from the Plasma Membrane upon Virus Infection , 2010, Journal of Virology.